Saturday, August 23, 2014

Top 10 Managed Healthcare Companies To Own In Right Now

Top 10 Managed Healthcare Companies To Own In Right Now: Provectus Pharmaceuticals Inc (PVCT)

Provectus Pharmaceuticals, Inc., incorporated on May 1, 1978, is a development-stage pharmaceutical company that is primarily engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The Company develops and focuses to license or market and sells its two prescription drug candidates, PV-10 and PH-10. The Company has transferred all its intellectual property related to over the counter (OTC) products and non-core technologies to its subsidiaries and designated, such subsidiaries as non-core to its primary business of developing its oncology and dermatology prescription drug candidates. The Company focuses on developing its prescription drug candidates PV-10 and PH-10. The Company is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer, and breast cancer. The Company is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atop ic dermatitis, a type of eczema. All of the Company's prescription drug candidates are in either the pre-clinical or clinical trial stage.

PV-10

As of December 31, 2011, the Company is developing PV-10, a sterile injectible form of rose bengal disodium (Rose Bengal), for direct injection into tumors. Its PV-10 is retained in diseased or damaged tissue but dissipates from healthy tissue. The Company had conducted Phase I and Phase IIstudies of PV-10 for the treatment of metastatic melanoma, and Phase I studies of PV-10 for the treatment of liver and breast cancers.

PH-10

The Companys prescription drug candidate PH-10 is an aqueous hydrogel formulation of Rose Bengal for topical administration to the skin. The Company is developing PH-10 for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis. In August 2011, the Company completed follow-up of a! ll Phase IIc patients.

Over-th e-Counter Pharmaceuticals

The Company had desi! gnated its subsidiary that holds its OTC products, GloveAid and Pure-ific, Pure-Stick, Pure N Clear as non-core. The Companys GloveAid is a hand cream with both antiperspirant and antibacterial properties, for the comfort of users hands during and after the wearing of disposable gloves. Its Pure-ific line of products includes two quick-drying sprays, Pure-ific and Pure-ific Kids, that immediately kill up to 99.9% of germs on skin and prevent regrowth for six hours. Pure-ific products prevent the spread of germs and thus complement its other OTC products designed to treat irritated skin or skin conditions, such as acne, eczema, dandruff and fungal infections. Its Pure-ific sprays have been designed with convenience in mind and are targeted towards mothers, travelers, and anyone concerned about the spread of sickness-causing germs.

The Companys acne products Pure-Stick and Pure N Clear work by decreasing the production of fats, oils and sweat that create an environment conducive to unchecked growth of bacteria. Secondly, the products also act to reduce the number bacteria already present. The Pure-Stick and Pure N Clear are applied topically to affected areas there are no safety concerns with healthy skin.

Advisors' Opinion:
  • [By Jake L'Ecuyer]

    Provectus Biopharmaceuticals (NYSE: PVCT) was also down, falling 3.02 percent to $3.01, letting out some air after the company's opening on the NYSE Friday.

  • [By Luke Jacobi]

    Provectus Biopharmaceuticals (NYSE: PVCT) was also down, falling 3.38 percent to $3.01, letting out some air after the company's opening on the NYSE Friday.

  • source from Top Penny Stocks For 2015:http://www.topstocksforum.com/top-10-managed-healthcare-companies-to-own-in-right-now.html

No comments:

Post a Comment